- 1. An isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) an amino acid sequence of SEQ ID NO:2,
 - b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,
 - a biologically-active fragment of at least 10 amino acid residues of the amino acid sequence of SEQ ID NO:2, and
 - d) an immunogenic fragment of at least 10 amino acid residues of the amino acid sequence of SEQ ID NO:2.
- 2. A pharmaceutical composition comprising the antibody of claim 1 in conjunction with a suitable pharmaceutical carrier.
- 3. (Once Amended.) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 1 comprising:
 - immunizing an animal with the polypeptide of SEQ ID NO:2 or an immunogenic fragment of at least 10 amino acid residues thereof under conditions to elicit an antibody response;
 - b) isolating animal antibodies; and
 - screening the isolated antibodies with the polypeptide thereby identifying a polyclonal antibody which binds specifically to the polypeptide of SEQ ID NO:2.
 - 4. An antibody produced by a method of claim 3.
- 5. A pharmaceutical composition comprising the antibody of claim 4 in conjunction with a suitable pharmaceutical carrier.



- 6. (Once Amended.) A method of making a monoclonal antibody with the specificity of the antibody of claim 1 comprising:
 - a) immunizing an animal with the polypeptide of SEQ ID NO:2 or an immunogenic fragment of at least 10 amino acid residues thereof under conditions to elicit an antib dy response;
 - b) isolating antibody producing cells from the animal;
 - c) fusing the antibody producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;
 - d) culturing the hybridoma cells; and
 - e) isolating from the culture a monoclonal antibody which binds specifically to the polypeptide of SEQ ID NO:2.
 - 7. A monoclonal antibody produced by a method of claim 6.
- 8. A pharmaceutical composition comprising the antibody of claim 7 in conjunction with a suitable pharmaceutical carrier.
 - 9. The antibody of claim 1, wherein the antibody is:
 - (a) a chimeric antibody;
 - (b) a single chain antibody;
 - (c) a Fab fragment; or
 - (d) a F(ab')₂ fragment.
- 10. The antibody of claim 1, wherein the antibody is produced by screening a Fab expression library.
- 11. The antibody of claim 1, wherein the antibody is produced by screening a recombinant immunoglobulin library.

111768

- 12. A diagnostic test for a condition or disease associated with the expression of human stem cell antigen-2 (SCAH-2) in a biological sample, the method comprising:
 - combining the biological sample with an antibody of claim 1, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex,
 and
 - b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 - 13. A diagnostic test of claim 12, wherein said antibody is labeled with a detectable label.
 - 14. An antibody of claim 1, labeled with a detectable label. Any fully
- 15. A method of diagnosing a condition or disease associated with the expression of human stem cell antigen-2 (SCAH-2) in a subject, comprising administering to said subject an effective amount of the composition of claim 14.
- 16. A method of detecting a polypeptide having an amino acid sequence of SEQ ID NO:2 in a sample, the method comprising:
 - incubating the antibody of claim 1 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
 - b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence of SEQ ID NO:2 in the sample.
- 17. A method of purifying a polypeptide having an amino acid sequence of SEQ ID NO:2 from a sample, the method comprising:
 - a) incubating the antibody of claim 1 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and

- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence of SEQ ID NO:2.
- 18. A method of treating cancer, comprising administering to a patient in need of such treatment an effective amount of an antibody of claim 1.
 - 19. A method of claim 18, wherein the cancer is prostate cancer.
 - 20. A method of claim 18, wherein the antibody is a monoclonal antibody.